[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multisystem-inflammatory-syndrome-in-children-mis-c\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multisystem-inflammatory-syndrome-in-children-mis-c":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641699","cardiovascular-assessment-5-years-after-mis-c-100641699",false,"NCT07659847","Cardiovascular Assessment 5 Years After MIS-C","Cardiovascular Evaluation 5 Years After Multisystem Inflammatory Syndrome in Children (MIS-C)","Inclusion Criteria:\n\n* For the MIS-C group: History of MIS-C diagnosed according to World Health Organization (WHO) criteria\n* For all participants: Written informed consent from a parent or legal guardian and, where applicable, assent\u002Fconsent from participants aged 16 years or older \u002F\n\nExclusion Criteria:\n\nMIS-C group:\n\n1. Known heart disease, including congenital heart disease.\n2. Significant chronic disease affecting growth, development, or daily functioning.\n\nControl group:\n\n1. Elimination diet.\n2. Competitive athletic training.\n3. Known heart disease, including congenital heart disease.\n4. Significant chronic disease affecting growth, development, or daily functioning.",true,"ALL",{"count":19,"type":20},90,"ESTIMATED","OBSERVATIONAL","Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system. Although acute cardiac abnormalities usually resolve, the long-term cardiovascular consequences of MIS-C remain uncertain. Previous follow-up of this cohort 2 years after MIS-C identified signs of subclinical cardiovascular abnormalities compared with healthy controls.\n\nThis cross-sectional study aims to evaluate cardiovascular health in individuals 5 years after MIS-C. Participants with a history of MIS-C will be compared with age- and sex-matched healthy controls using cardiovascular imaging, vascular assessments, cardiopulmonary exercise testing, and biomarkers of endothelial injury.",[24,25],"Multisystem Inflammatory Syndrome in Children (MIS-C)","SARS-CoV-2 Infection",[27,28,29,30,31,24,32],"Pediatric Inflammatory Multisystem Syndrome (PIMS)","SARS-CoV-2","Endothelial Dysfunction","Cardiovascular Health","Long-Term Outcomes","Arterial Stiffness","RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":37},"2025-11-22",{"date":41,"type":20},"2027-03-31",{"name":43,"class":44},"Medical University of Warsaw","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878","NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study","0 Years","20 Years",{"count":57,"type":20},5000,"The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,24,81,82,83],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Kawasaki Disease","Coagulation Disorder","Down Syndrome","2026-03-31",{"date":86,"type":37},"2026-04-06",{"date":88,"type":37},"2020-03-05",{"date":90,"type":20},"2027-07",{"name":92,"class":44},"Duke University",51]